October 01, 2020 TCT Connect 2020
Keystone Heart is pleased to share the results from REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR) have been accepted for presentation in a late-breaking clinical science session at the upcoming Cardiovascular Research Foundation TCT Connect Meeting.
The REFLECT Phase II study is a prospective, randomized, multi-center study evaluating the safety and effectiveness of the TriGUARD 3™ Cerebral Embolic Protection Device during TAVR.
|Presentation Title :||REFLECT Phase II: A Randomized Trial of a Cerebral Embolic Protection Device During Transcatheter Aortic Valve Replacement (TAVR)|
|Date and Time :||October 15, 2020 at 11:20 am Eastern Time|
|Lecturer :||Jeffrey W. Moses, MD, Director, Interventional Cardiovascular Therapeutics and Professor of Medicine at New York-Presbyterian/Columbia University Medical Center; REFLECT Trial Study Chairman|
Join the session by registering at www.TCTConnect.com
The TriGUARD 3™ CEP Device is the only CE Marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures